Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease which presents a grave prognosis for diagnosed patients. Nintedanib (a triple tyrosine kinase inhibitor) and pirfenidone (unclear mechanism of action) are the only approved therapies for IPF, but have limited e...

Descripción completa

Detalles Bibliográficos
Autores principales: Overed-Sayer, Catherine, Miranda, Elena, Dunmore, Rebecca, Liarte Marin, Elena, Beloki, Lorea, Rassl, Doris, Parfrey, Helen, Carruthers, Alan, Chahboub, Amina, Koch, Sofia, Güler-Gane, Gülin, Kuziora, Michael, Lewis, Arthur, Murray, Lynne, May, Richard, Clarke, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Interstitial Lung Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476277/
https://www.ncbi.nlm.nih.gov/pubmed/32709610
http://dx.doi.org/10.1136/thoraxjnl-2019-214000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476277/
https://www.ncbi.nlm.nih.gov/pubmed/32709610
http://dx.doi.org/10.1136/thoraxjnl-2019-214000

Ejemplares similares